{"organizations": [], "uuid": "721a087468cf51c3b38b4e7cacb1ff5f9f2e8eb2", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/5", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/05/22/globe-newswire-kane-biotech-appoints-pharmaceutical-executive-rashieda-gluck-to-board-of-directors.html", "country": "US", "domain_rank": 767, "title": "Kane Biotech Appoints Pharmaceutical Executive Rashieda Gluck to Board of Directors", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.002, "site_type": "news", "published": "2018-05-22T16:23:00.000+03:00", "replies_count": 0, "uuid": "721a087468cf51c3b38b4e7cacb1ff5f9f2e8eb2"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/05/22/globe-newswire-kane-biotech-appoints-pharmaceutical-executive-rashieda-gluck-to-board-of-directors.html", "ord_in_thread": 0, "title": "Kane Biotech Appoints Pharmaceutical Executive Rashieda Gluck to Board of Directors", "locations": [], "entities": {"persons": [{"name": "rashieda gluck", "sentiment": "negative"}, {"name": "gluck", "sentiment": "none"}, {"name": "rashieda", "sentiment": "none"}, {"name": "rivka) gluck", "sentiment": "none"}, {"name": "mark ahrens-towns", "sentiment": "none"}], "locations": [{"name": "manitoba", "sentiment": "none"}, {"name": "winnipeg", "sentiment": "none"}], "organizations": [{"name": "kane biotech inc.", "sentiment": "negative"}, {"name": "kane biotech appoints pharmaceutical executive", "sentiment": "negative"}, {"name": "aurinia pharmaceuticals", "sentiment": "none"}, {"name": "glaxosmithkline", "sentiment": "none"}, {"name": "qu biologics", "sentiment": "none"}, {"name": "vifor pharma", "sentiment": "none"}, {"name": "corporation’s board of directors", "sentiment": "none"}, {"name": "novartis", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "WINNIPEG, Manitoba, May 22, 2018 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (OTCQB:KNBIF), (the “Corporation” or “Kane Biotech”) is pleased to announce it has appointed Rashieda (Rivka) Gluck to the Corporation’s Board of Directors. With over 20 years of experience in the global pharmaceutical, biotechnology, and life science industries, Ms. Gluck’s career has spanned all levels and functions in clinical development. As an executive, her focus has been on leading the strategic planning and successful implementation of high quality clinical development programs.\nMs. Gluck’s leadership in the life sciences industry spans both publicly-traded and private companies. Currently, Ms. Gluck is on the executive management team of Aurinia Pharmaceuticals, developing and implementing their overall corporate strategy. She also leads all clinical operations for their lead drug, voclosporin. Prior to that, Ms. Gluck has held management-level, clinical operations roles at innovative companies including Qu Biologics, Vifor Pharma, Novartis, and GlaxoSmithKline, among others.\nMark Ahrens-Townsend, President & CEO of Kane Biotech, commented, “We are proud to appoint Rashieda to our Board of Directors, bringing her wealth of experience in overseeing and effectively running clinical operations in many environments. She is ideally suited to help guide Kane Biotech at this time with the number of clinical and efficacy studies we currently have ongoing for multiple pet and human health-related conditions. Her clinical development knowledge, as well as her ability to run efficient programs and her versatility in multiple aspects of healthcare and life sciences, is a solid strategic match for the broad applicability of our biofilm-preventing technologies.”\nMs. Gluck currently serves as Senior Vice President of Global Clinical Operations at Aurinia Pharmaceuticals Inc. since February 2018 and has also served as its Vice President of Clinical Operations since January 1, 2016. She previously served as Vice President of Clinical Operations at Qu Biologics Inc. and was responsible for leading their clinical programs and providing strategic direction for the clinical development of their platform immunotherapeutic treatments in multiple disease indications. Prior to that, Ms. Gluck served as Vice President of Clinical Operations at Aspreva in New Jersey and was responsible for the successful integration of the global clinical operations department post acquisition by Zurich-based Vifor Pharmaceuticals. At Vifor, she served as Vice President and Head of Global Clinical Operations where she was a member of the Research, Development, and Leadership team and continued to build and lead the clinical research department in Zurich and hold overall accountability for the execution and delivery of all global clinical programs. In her career, Ms. Gluck served in increasingly senior positions at major pharmaceutical companies including Novartis, Organon, and GSK. Ms. Gluck holds a B.Sc. in Nursing from the University of British Columbia.\nAbout Kane Biotech\nKane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms.\nThe Corporation has a portfolio of biotechnologies, intellectual property (75 patents and patents pending, trade secrets and trademarks) and products developed by the Corporation’s own biofilm research expertise and acquired from leading research institutions. StrixNB™, DispersinB®, Aledex®, bluestem™, AloSera™, coactiv+™ and Kane® are trademarks of Kane Biotech Inc. The Corporation is listed on the TSX Venture Exchange under the symbol \"KNE\" and on the OTCQB Venture Market under the symbol “KNBIF”.\nFor more information, please visit www.kanebiotech.com or contact:\nMark Ahrens-Townsend\nPresident & CEO\nKane Biotech Inc.\n+1 (204) 477-7592 ir@kanebiotech.com\nTirth Patel\nVice President - Investor Relations\nEdison Advisors\n+1 (646) 653-7035 tpatel@edisongroup.com\nNeither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.\nCaution Regarding Forward-Looking Information\nThis press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making , and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to the Company’s: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of the Company to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by the Company with applicable securities regulatory authorities, available at www.sedar.com . The Company cautions that the foregoing list of factors that may affect future results is not exhaustive.\nThese risks and uncertainties should be considered carefully undue reliance should not be placed on the . Although the contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot provide assurance that actual results will be consistent with these . The Company undertakes no obligation to update or revise any forward-looking statement.\nSource:Kane Biotech Inc.", "external_links": ["https://www.globenewswire.com/NewsRoom/AttachmentNg/49de765b-f1e6-471f-9a91-49dc3dd4eb6b"], "published": "2018-05-22T16:23:00.000+03:00", "crawled": "2018-05-22T17:52:08.008+03:00", "highlightTitle": ""}